Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Transitional Cell Carcinoma. Found 16 abstracts

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European urology focus. 2019 Mar;5(2):242-9.   PMCID: PMC5712487
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
Fatima N, Canter DJ, Carthon BC, Kucuk O, Master VA, Nieh PT, Ogan K, Osunkoya AO. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. The Canadian journal of urology. 2015 Jun;22(3):7783-7.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Norberg SM, Oros M, Manucha V, Eun D, Bilusic M. Loss of e-cadherin and retinoblastoma genes in a case of urothelial carcinoma with scrotal metastasis. The Canadian journal of urology. 2015 Apr;22(2):7755-7.
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901.   PMCID: PMC4050203
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye [Letter]. J Clin Oncol. 2014 Dec 20;32(36):4171-2.
Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, Shariat SF, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol. 2014 Jan;32(1):47e9-14.
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32.   PMCID: PMC4687398
Canter D, Simhan J, Smaldone MC, Lebed B, Tokar JL, Wu KN, Uzzo RG, Gustafson KS, Patchefsky AS, Plimack ER, Hoffman JP, Kutikov A. Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. Urology. 2012 Feb;79(2):e9-10.   PMCID: not NIH funded
Baselli EC, Greenberg RE. Maintenance therapy for superficial bladder cancer. Oncology (Huntingt). 2001 Jan;15(1):85-8; discussion 88-91.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International journal of cancer. 2000 Nov 20;89(6):514-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Transitional Cell Carcinoma

Transitional Cell Carcinoma pathology drug therapy Urinary Bladder Neoplasms therapeutic use Aged Middle Aged methods Female Male 80 and over Aged Neoadjuvant Therapy Retrospective Studies Treatment Outcome Neoplasm Invasiveness Antineoplastic Combined Chemotherapy Protocols secondary surgery Adjuvant Chemotherapy Neoplasm Staging Cystectomy adverse effects Human statistics & numerical data Lymphatic Metastasis Cisplatin Doxorubicin Bladder Neoplasms Antineoplastic Agents Urothelial carcinoma Disease-Free Survival Combined Modality Therapy Methotrexate Protective Agents chemistry analogs & derivatives Granulocyte Colony-Stimulating Factor analysis ultrastructure Perioperative chemotherapy therapy mortality administration & dosage genetics Prospective Studies Drug Administration Schedule Local Neoplasm Recurrence Bladder cancer Kaplan-Meier Estimate Urologic Neoplasms Lymph Node Excision Survival Rate Lymph Nodes Mitomycin Antineoplastic Antibiotics Vinblastine Proportional Hazards Models Prognosis Hyperplasia Margins of Excision immunology muscle invasion Interferons Treatment Cadherins Postoperative Complications Human Chromosomes-Pair 9 diagnosis Clone Cells Kidney Function Tests Non-muscle-invasive Anticarcinogenic Agents Immunologic Adjuvants Mutation Oncologists Propensity Score Non-US Gov't Support Nephrectomy Research Design Thiotepa chemically induced physiology Drug Dose-Response Relationship Maximum Tolerated Dose Fatigue Skin Neoplasms drug Pancreatic Cyst Adult Pancreatic Ducts Age Factors epidemiology Survival Analysis Risk Factors Chromosome Deletion vinblastine Propensity-score Monoclonal Antibodies-Humanized Gene Expression Profiling Ureter Intravesical Administration Single-Blind Method Disease Progression Urologic Surgical Procedures Multivariate Analysis Mycobacterium bovis Glomerular Filtration Rate pd-1 Review Cell Cycle Checkpoints Filgrastim First-line chemotherapy CTLA-4 Antigen pd-l1 Salvage Therapy Nucleic Acid Repetitive Sequences Pancreatic Neoplasms B7-H1 Antigen dosage Tumor Biomarkers bladder cancer Follow-Up Studies Muscle Neoplasms gemcitabine plus cisplatin Retinoblastoma Genes etiology Robot-assisted surgery ctla-4 Renal-function changes Preclinical Drug Evaluation drug effects doxorubicin Micropapillary physiopathology Microsatellite Repeats Patient Selection US Gov't Support-PHS Squamous Cell Neoplasms methotrexate Immunological Antineoplastic Agents Biological Tumor Markers Hematuria Carcinoma in Situ Programmed Cell Death 1 Receptor cisplatin Phase II Clinical Trials as Topic Deoxycytidine antagonists & inhibitors Multicenter Studies as Topic Medical Oncology
Last updated on Friday, January 03, 2020